Discussion  by unknown
Congenital Heart Disease d’Udekem et al
C
H
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obtain. The surgeons examined in the present study were
not all working in contemporary eras, limiting the validity
of the intersurgeon comparison. In particular, patients
treated in an earlier era were older at their repair and had
more frequently undergone previous palliation. Although
the analyses were adjusted for these differences, the
potential for differences in unmeasured confounders to
have influenced the results remained. Additionally, it would
not be impossible that the indications for reoperation varied
slightly during the study period. The main findings of the
present study should not have been affected by this
limitation. Patients treated in the early era were, in the
contemporary period, followed by the same teams as those
treated later and were, therefore, subjected to the same
indication criteria. Also, the main variations among the
surgeons were observed for surgeons 2 and 5, who were
operating during the same era.
The strengths of the study were the quality of our
follow-up, that Australian patients with congenital heart
disease are treated only at a limited number of centers,
and that the decision for reintervention for all patients
was determined by teams closely collaborating rather than
by individual surgeons.
CONCLUSIONS
The analysis of the reoperation rate during the long-term
follow-up of transatrial repair of tetralogy of Fallot
identified variability in the outcomes among surgeons. The
observed differences in the postrepair RVOT gradient among
surgeons suggest that variability could exist in the amount of
opening of the RVOT among surgeons. If so, this might
explain the observed intersurgeon variability in late out-
comes. If correct, an optimal amount of opening for the
RVOT might exist that would lead to a minimal rate of
reintervention. The analysis of intersurgeon variability in
outcomes should be encouraged, because it will lead to
improvements in the outcomes after cardiac surgery.
The authors would like to thank Mr Bill Reid for professional
preparation of the illustrations.
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Dr Marshall Jacobs (Philadelphia, Pa). This intriguing
analysis was based on the premise that analyzing the variation in
outcomes among individual surgeons who purport to be doing
the same operation could lead to a better understanding of the
essential features of the operation. In that respect, it is of general
interest and specific interest. Specifically, surgical repair of
tetralogy of Fallot is not a cure. The resultant physiology is not
completely normal, and many patients will require interventions
later in life.
Proponents of transatrial repair have postulated that it will
result in a reduced incidence of RV dilatation requiring later
implantation of a pulmonary valve. These results in Melbourne
for>3 decades are truly outstanding, with probably the lowestery c March 2014
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Drate of mortality in any series of operations for tetralogy of Fallot
of this size. In this very large cohort, transannular patching was
performed in 75% of the cases. At 15 and 25 years, only 9%
and 15% had undergone implantation of a pulmonary valve,
respectively. At 25 years, the overall freedom from reintervention
was 25%.
Twelve years ago, at a meeting of this Association, a report was
presented of a series of patients who had undergone repair in
infancy of tetralogy of Fallot using a transventricular approach.
The presentation was discussed by an outstanding senior
surgeon from Melbourne who had made the following, not quite
excoriating, comment: ‘‘What worries me is that so little
information is given about the right ventricles of these patients.’’
Dr Roger Mee called for ‘‘.objective data from echocardiograms
and exercise testing.’’
Dr d’Udekem, in your report describing Melbourne’s large
consecutive transatrial repair cohort, you explained that
pulmonary valve replacement was usually undertaken when severe
pulmonary regurgitation was found in the presence of RV
dilatation, RV dysfunction, or symptoms of exercise intolerance.
Echocardiographic data at an average follow-up of 12 years
showed that pulmonary regurgitation was estimated to be severe
in 193 patients and moderate in 96 patients. These numbers
were far greater than the number who had undergone pulmonary
valve implantation.
Your analysis of the variation in the rate of reoperation
among surgeons is fascinating. One wonders, however, whether
freedom from various types of reintervention is the best
method to evaluate the effectiveness of an operative
strategy. Also, does it adequately discriminate among the results
achieved by the individual surgeons or is the rate of reoperation
actually a minimal estimate of those patients with troubled
right ventricles?
My first question is, would not the overall assessment and
the specific differences among the individual surgeons’
outcomes be even more informative if the analysis were based
on objective data of the RV size and function, regurgitant fraction,
and exercise capacity, rather than entirely on the rate of
reoperation?
Dr d’Udekem. Thank you very much. I think that is a very
excellent point. What we are concerned with is the functional
capacity of these patients.
MRI data are very difficult to obtain. We do not have in
Melbourne the research MRI facilities necessary to do a cross-
sectional study of our Fallot population. The echocardiographic
data are subject, as you know, to subjectivity. It would be difficult
to have a precise evaluation of RV function and RV volumes.
However, we do have actually exercise studies for the patients
from Victoria. I did not think to consider the difference among
the surgeons, but I will promptly do that as soon as I am back.
It is an excellent idea.
Dr Jacobs. Thank you. My second question relates to the
analysis of variation in outcomes among the individual surgeons
as a method of identifying the characteristics of an optimal
operative procedure. The competing objectives of relieving
outflow tract obstruction and minimizing the volume burden
imposed by pulmonary insufficiency will be influenced by both
the individual patient anatomy and the individual surgeon’sThe Journal of Thoracic and Catechnique. This suggests the possibility of a ‘‘sweet spot’’ at which
one does enough resection through a minimal incision to relieve
obstruction but does not cause severe pulmonary insufficiency.
You pointed out that the surgeon with the lowest incidence of
pulmonary valve replacement had a very high rate of patients
requiring reintervention for right ventricular outflow tract
obstruction. So, my second question is, has this study led you to
an assessment of what would be an acceptable gradient to leave
at the end of the operation? That is, where is the ‘‘sweet spot’’
between relief of obstruction and disruption of competence of
the pulmonary valve? Another way of asking, is if you took the
patients of surgeon 2 and surgeon 5 at late follow-up and had
them exercise, which group would perform better, the group
who had residual obstruction or the group who had had wide
open regurgitation after their initial repair?
Dr d’Udekem. It is a very important point, and I would like to
elaborate a little bit on this. The real answer is we do not know
exactly what we have to do with the outflow tract of these
patients. We know that RV dilatation is bad. You do not want to
put a valved conduit in these patients, and once you place the
first valved conduit, you start an eternal circle in which you are
going to have to keep performing reoperations on these patients.
When you study these patients with tetralogy of Fallot, they
go through different stages in life. They are born with RV
hypertrophy, they dilate, you put a conduit in them, the next
reoperation will be for obstruction, they start becoming
hypertrophic again, and what we do not know is at the end what
kind of heart does it make? We need the 40-year perspective.
Some of these patients we see have been coming back after
40 years with wrecked biventricular function, and if the origin of
their dysfunction was the initial RV dilatation, we should perhaps
avoid RV dilatation at all costs.
The old textbooks would tell you that it is bad to leave RV
outflow tract obstruction, but that is no longer the case with the
contemporary technique. We have presented, but not published,
our results with patients left with residual obstructions>40 mm
Hg. They have not died and they have been fairly asymptomatic,
not by an exercise study, but they have been fairly asymptomatic.
Thus, we do not know exactly whether we have to reoperate when
they have RVOT obstruction.
Now, there is something that can help you. You have to look at
the age, and I do not mean the age of the patient. I think you have to
look at the age of the surgeon. Thus, if you are a senior surgeon or
in the middle of your career, you can have as many reoperations for
RVOT obstruction as you want—you are still going to keep your
job. However, if you are a young surgeon and you are starting at
a new place, I would recommend not having a 25% rate of
reoperation at 5 to 10 years because I do not think you are going
to look good. So, if you want to look better, if I can have my extra
slide here, I can help you a little bit on how to look good, because
we plotted the echocardiographic data before hospital discharge
against the risk of reoperation, all reoperations and those for
dilatation and for obstruction. You will find that the HR of
reoperation was basically around 1 at a 15 to 20-mm Hg gradient.
Again, I do not say that we needed to do these reoperations for
RVOT obstruction. That was a historical series. These are the
indications you will receive from your mainstream cardiologists.
At a 30-mm Hg gradient, you will have a HR of 2, you haverdiovascular Surgery c Volume 147, Number 3 887
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Ddoubled the risk of reoperation, and at a 50-mm Hg gradient, you
have quadrupled the risk of reoperation.
Dr Jacobs. Well, I think we learned a great deal from this
interesting analysis. The concept itself is excellent, and I888 The Journal of Thoracic and Cardiovascular Surgrecommend your report to thosewhowant to pursue this interesting
topic. I hope in the future you will be able to analyze some
physiologic data and perhaps data on the length of the outflow tract
incision, which you speculated was important. Thank you.ery c March 2014
